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1. Introduction
Kidney may undertake normal function immediately after transplantation or even several or
over a dozen days delay. Absence of normal renal transplant function may lead to acute kidney
injury (AKI), nephrotic syndrome (NS) and chronic kidney disease (CKD). Acute kidney
injury (AKI) is characterized functionally by a rapid decline in the glomerular filtration rate
(GFR), and biochemically by the resultant accumulation of nitrogenous wastes such as blood-
urea nitrogen and creatinine (Devarajan, 2010). Nephrotic syndrome (NS) is a nonspecific
disorder in which the kidneys damage is accompanied by a leak of large amounts of protein
(proteinuria at least 3.5 grams per day per 1.73m2 body surface area) from the blood into the
urine. Nephrotic syndrome is a disorder of the glomerular filtration barrier. The multiprotein
complex between adjacent podocyte foot processes the slit diaphragm, is essential to the
control of the actin cytoskeleton and cell morphology. Signaling from slit diaphragm proteins
to the actin cytoskeleton is mediated via the Rho GTP-ases. These are thought to be involved
in the control of podocyte motility, which has been postulated as a focus of proteinuric
pathways (Hull & Goldsmith, 2008). It is common belief that nephrotic syndrome after
transplantation results mainly from recurrence of renal disease in transplanted kidney and not
defective graft function. Chronic kidney disease (CKD) – it is kidney damage for ≥3 months,
defined by structural or functional abnormalities of the kidney, with or without decreased
GFR, manifested by either pathological abnormalities or markers of kidney damage, including
abnormalities of blood or urine or abnormalities in imaging tests (Ahmad et al., 2006).
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2. Markers of nephrons damage
After kidney transplantation it is particularly important to monitor the biomarkers which
allow to detect progress in disease process and determine which functional parts of kidney are
going to be damaged, to enable application of a quick appropriate treatment (Lisowska-Myjak,
2010; Alachkar et al., 2010; Metzger et al., 2010). Administration of immunosuppressants for
preventing renal graft rejection may lead to progressive damage to the renal tissue (interstitial
fibrosis, tubular micro calcifications, atrophy of renal tubules) caused by high toxicity of
suppressing drugs. Cyclosporine A(CsA), tacrolimus, mycophenolate mofetil, basiliximab,
prednizon and sirolimus (rapamycin) are commonly used in immunosuppressive therapy
following kidney transplantation. Cyclosporine A and tacrolimus generate immunosuppres‐
sive action by binding to cyclofiline and inhibiting the action of calcineurin 2, which stimulates
proliferation and differentiation of lymphocytes T. Cyclosporine A inhibits synthesis of
lymphokines by lymphocytes T. Lymphokines synthesized by lymphocytes T stimulate
immunological system and have the ability to „kill” inflammatory and neoplastic cells.
Mycophenolate mofetil selectively inhibits inosine monophosphate dehydrogenase, a basic
enzyme in guanosine synthesis. Mycophenolate mofetil inhibits proliferation of lymphocytes
T and B after stimulation with antigenes, cytokines and mitogens. Basiliximab similarly to
Daclizumab, blocks receptors for IL-2.
Majority of renal pathological changes concern glomerules, proximal and distal tubules as well
as vascular endothelium. At first renal proximal tubular cells (Fig.1.) demonstrating highest
metabolic activity, possessing high amounts of mitochondries, lysosomes and peroxysomes
are damaged. Remaining sections of nephron such as: Henle’s loop, distal tubules and
collecting tubules are usually damaged later. There are numerous biomarkers that identify
injury the area of the renal nephron, such as the glomerulus, the proximal, and the distal tubule.
2.1. Biomarkers of renal glomeruli
The oldest biomarkers of renal glomeruli injure are serum urea and creatinine as well as
clearance of endogenic creatinine, which similarly to inulin (gold standard in GFR determi‐
nation) is excreted to urine and not absorbed in renal tubules. Clearance of endogenic creati‐
nine is 10-20% higher than clearance of inuline, which is a result trace excretion of creatinine
by renal tubules (Finney et al., 2000).
Cystatin C (CYC) is a cysteine protease inhibitor that is stably secreted from all nucleated cells,
freely filtered through the glomerulus, and completely reabsorbed by the proximal tubules.
During efficient function of proximal renal tubules there are traces of urinary CYC, independ‐
ent of age and body mass. Given that cystatin C is not normally found in urine in significant
amounts, the elevated level of urinary cystatin C may display dysfunction of tubular cells and
tubulointerstitial disease. Concentration of CYC in normal urine accounts 0.03-0.3 mg/L (Filler
et al., 2005). Increase in serum CYC is proportional to decrease in GFR (Campo et al., 2004 ). It
was reported that serum CYC correlated better with GFR than creatinine (Filler et al., 2005;
Schuck et al., 2004). After renal transplantation CYC concentration increased simultaneously
to AKI development, because of decreased reabsorption from damaged tubules. Therefore
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urinary concentration of CYC may be treated as a good marker of the proximal tubules and
effective biomarker of delayed renal graft function due to lack of diurnal changes, and high
stability in routine conditions of urinary storage, urinary CYC may be determined in single
urinary samples. Urinary CYC / creatinine ratio is a good indicator of renal tubules dysfunction
as in disorders of renal tubules, urinary CYC concentration may increase even 200 fold (Uchida
& Gotoh, 2002; Lisowska-Myjak, 2010). Two fully automated and quick immunological
methods for CYC determination: turbidimetric PETIA (particle enhanced immunoturbidimet‐
ric assay) and nephelometric – PENIA (particle enhanced nephelometric immunoassay) were
developed in 1994-1997. Presently measurements of urinary CYC are utilized mainly with a
Figure 1. Nephron structure
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PENIA method designed primary for CYC determination in serum (Herget-Rosenthal et al.,
2004). PENIA method (particle enhanced nephelometric immunoassay)allows for a CYC
detection at a concentration of 0.05-10.47 mg/L.
Proteinuria reflects increased filtration plasma proteins to tubular fluid and disturbed protein
reabsorption by renal proximal tubular cells (Haraldsson & Sörensson, 2004; Halbesma et al.,
2006; Giorgio et al., 2004). Proteinuria over 0.5g/24 hours is a marker the severity of the tubular
damage, independent risk factor of progressive tubular-interstitial fibrosis and strong
predictor of the end-stage renal insufficiency. Evident proteinuria is symptomatic for estab‐
lished renal damage significantly connected with decreased GFR (Abbate et al., 2006; Eddy,
2004; Tryggvason & Pettersson, 2003; Zoja et al., 2003; Ofstad & Iversen, 2005). Even minimal
proteinuria lasting one year after renal transplantation is an indicator of a poor renal graft
function and may be a risk factor for renal graft failure (Kang et al., 2009). Urinary protein is
a non-invasive and easy to perform parameter. It was reported that proteinuria (<0.5 g/24 h)
occurred in half of patients within 3 month after renal transplantation (Sancho Calabuig et al.,
2009). Higher than standard doses of everolimus (EVL) resulted in an increase of proteinuria.
Therefore the standard doses of EVL are recommended which seems to be suitable for
protecting against an acute graft rejection with better prognosis of renal function in longer
perspective (Loriga et al., 2010). As chronic allograft nephropathy (CAN) is the most frequent
reason for late loss of graft, immunosuppression with mycophenolate mofetil significantly
improves graft function and in such circumstances evaluation of proteinuria seems to have
prognostic value (Grebe et al., 2004).
Albuminuria as a marker of glomerular filtration is more sensitive than proteinuria. Urinary
albumin border value of 200 μg/min differentiates patients with albuminuria and proteinuria.
Increase in urinary albumin excretion above 200 μg/min (macroalbuminuria) indicates damage
to glomerular filtration membrane, a start of evident proteinuria, progression of kidney disease
and cardiovascular changes (Ruggenenti & Remuzzi,2006). After exceeding maximal reab‐
sorption capacity of proximal tubular cells, protein of primary urine appeared in final urine
(Luke, 1999; Remuzzi et al., 2006; Zoja et al., 2003). Excessive accumulation, in proximal tubular
cells, plasma proteins excreted to primary urine, induced increase in local expression of
cytokines and chemokines, which presence in final urine is a specific indicator of development
and extent of renal damage (Lisowska-Myjak, 2010; Alachkar et al., 2010). Renal tubular cells
exposed to increased amounts of filtered plasma proteins resulting cell injury. Microalbumi‐
nuria predicts a loss of renal graft. Determination of urinary albumin and UACR-urine
albumin-to-creatinine ratios (UACR) are particularly recommended indicators for detection
of changes in transplanted kidney (Erman et al., 2011). Microalbuminuria is considered to be
a better indicator of kidney transplant condition than proteinuria (Bandukwala et al., 2009).
Albuminuria, the marker of renal glomeruli damage and chronic damage of transplanted
kidney, which may also reflect interstitial inflammatory process, is considered a predictor of
long-term allograft outcomes in a kidney graft recipient (Nauta et al., 2011).
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2.2. Adhesion molecules connected podocytes with basement membrane
Integrin α3 and integrin β3 are particularly recommended biomarkers for monitoring the
function of transplanted kidney both at early and remote period after transplantation. The
integrin family of cell adhesion proteins promotes the attachment and migration of cells on
the surrounding extra cellular matrix (ECM). The signals initiated by integrin binding to ECM
proteins are necessary to maintain cell survival, adhesion, migration and invasion. Integrins
are transmembrane glycoproteins consisting of two units: α and β. Beta1 family of integrins
represents the major class of cell substrate receptors with specificities primarily for collagens,
laminins, and fibronectins (Srivastava et al., 2011).
Vascular cell adhesion molecule-1 (VCAM-1), sVCAM-1 (CD106) (soluble vascular cell
adhesion molecule 1) and anti-intercellular adhesion molecule-1 (ICAM-1) The ICAM and
VCAM – members of the immunoglobulin (Ig) superfamily, are the chief endothelial cell
proteins that are recognized by the white cell integrins. Elevated urinary sVCAM-1, IL6, sIL6R
and TNFR1 concentrations indicate an acute kidney transplant rejection in the first 2 weeks
after transplantation (Reinhold et al., 2012). It was reported that increased urinary concentra‐
tions of sICAM-1, determined by ELISA, occured in patients with acute renal graft rejection
(Teppo et al., 2001), and in people with proteinuria, high concentrations of sVCAM and sICAM
were observed (van Ree et al., 2008). Recently a non-invasive monitoring of the acute renal
graft rejection by determination of cell adhesion molecules has been recommended (Gwinner,
2007).
3. Biomarkers of proximal tubules
α1-microglobulin (α1M) is a 27 kDa glycoprotein related to retinol binding protein synthesized
by liver cells, engaged in immunoregulation (binds lymphocytes T and B) and heme catabo‐
lism. Determination of α1M (stable in acid urine) is a sensitive indicator of renal proximal
tubules damage (Guder, 2008; Lisowska-Myjak, 2010; Câmara et al., 2009). (Teppo et al.,
2004) reported that six month after transplantation, 32% of patients presented microalbumi‐
nuria. Evaluation of a damage to renal proximal tubules, on the basis of an increase in urinary
α1M concentration may be a consequence to a deterioration of glomerular filtration. Increase
in α1M /creatinine ratio is an early and sensitive indicator of a poor function of the transplanted
kidney, and indicates a poor prognosis of long term survival of renal transplanted patients
(Teppo et al., 2004).
Retinol binding protein (RBP), protein of the lipocalin family, synthesized mainly in a liver,
supplies retinol to peripheral tissues. RBP removed from plasma by glomerular filtration is
subsequently absorbed and catabolized in renal proximal tubules. Increased urinary RBP is
caused by a disorder in glomerular filtration and reabsorption in renal proximal tubules
(Guder, 2008; Kuźniar et al., 2006; Uchida & Gotoh, 2002; Câmara et al., 2009). It seems that
urinary RBP is a better biomarker of proximal tubules damage than β2M, as RBP has greater
stability in acid urine than β2M and renal insufficiency is only a clinical situation where an
increase in urinary RBP concentration is observed.
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Adenosine deaminase binding protein (ABP) is a glycoprotein (120-kDa) present in lungs,
liver, placenta and brush border of renal proximal tubules. Increased expression in the urinary
ABP is considered an early indicator of acute renal injury (AKI). Increase in urinary ABP was
reported in patients with ischemia - without sepsis, after kidney transplantation, after toxic
renal tubules damage, and in newborn with sepsis. Recently published opinion suggested that
ABP to be the best marker of acute renal damage, better than β2-M or α1-M (Bagshaw, 2007).
As ABP excretion was higher among kidney transplants recipients than in people with normal
renal function, ABP is considered as a good indicator for detection of renal graft failure (Iglesias
& Richard, 1994).
β2-microglobulin (β2M) is a membrane protein of major histocompatibility complex HLA. β2M
excretion is used for evaluation of nephrotoxic renal damage (aminoglycoside antibiotics,
heavy metal salts) (Guder, 2008). It should be noted that determination β2M for evaluation
function of transplanted kidney may be ambiguous because of coexistence of many factors
influencing its plasma and urinary concentration (e.g. toxic drugs action, ischemia reperfusion
complications or renal graft rejection). Measurement of urinary β2M may be helpful in
evaluation of the condition of transplanted kidney, however the interpretation of result should
be careful because of the plurality of factors influencing β2M plasma concentration, renal
filtration ability and tubular function (Kuźniar et al., 2006).
4. Markers of inflammatory reaction connected with acute renal failure
Neutrophil gelatinase-associated lipocalin (NGAL) is a glycoprotein expressed and secreted
by immune cells, trachea, stomach, colon, and injured kidney epithelial cells as an monomer
(22 kDa), dimer or trimer. NGAL may complex with collagenase type IV of human neutrophils
named gelatinase B or metalloproteinase 9 (MMP-9) creating heterodimer (125 kDa) (Flower,
1996). NGAL binds and transports small lipophilic molecules e.g. free fatty acids, retinoids,
arachidonic acid, and steroids (Mishra et al., 2003). NGAL is considered as provider iron to
proximal renal tubules. Iron stimulates oxygenase synthesis which protects renal tubules cells.
NGAL may be applied as a predictor of ischemic or toxic renal damage, before development
of a full symptomatic renal insufficiency. Increase in urinary NGAL concentration is early,
sensitive and non-invasive marker of renal damage correlating with intensity and time of
ischemia and preceding increase in other markers such as hexosaminidase or β2-microglobu‐
lin. A strict correlation between NGAL concentration and degree of proteinuria was demon‐
strated (Flower, 1996). NGAL activated formation of nephrons in early step of renal
development demonstrates a protective action in kidney (Mori & Nakao, 2007). Low molecular
weight, resistant to degradation NGAL is easily excreted by cells of thick ascending arm of
Henry loops and collective tubules into urine both free and in complex with MMP-9. Increase
in urinary excretion of NGAL is observed several hours after stimuli of nephrotoxic factor. As
concentration of urinary NGAL correlates with plasma NGAL concentration, NGAL may be
an useful marker in diagnostics of renal diseases (Nickolas et al., 2008). There is an opinion
that NGAL is the most promising biomarker for diagnosis of acute renal injury (AKI) in acute
renal graft dysfunction (Halawa, 2011; Ting et al., 2012; Hollmen, 2011).
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Kidney injury molecule-1 (KIM-1) is a transmembrane glycoprotein receptor (104 kDa)
appearing as KIM-1a and KIM 1b. KIM-1 is produced in large quantities in renal proximal
tubules after a toxic or ischemic damage. It is assumed that direct cause of KIM-1 induction is
an increase of the protein concentration in glomerular ultrafiltration and presence of urinary
protein casts favoring tubular obstruction, mechanical stress and an increase in glomerular
pressure. An increase in urinary KIM-1 excretion is specific to the ischemic renal damage and
is practically independent of chronic renal insufficiency or renal tract infection (Nickolas et al.,
2008; Melnikov & Molitoris, 2008). It was reported that KIM-1 extracellular domain (fragment
90 kDa) reaches urine after cleavage by metalloproteinase (Han et al., 2002; Waanders et al.,
2010). Urinary KIM-1 is particularly important in the diagnosis of the acute transplanted
kidney insufficiency(AKI) (Halawa, 2011). As in renal graft recipients, contrary to urinary
NGAL or IL-18, KIM determination gives better possibility for predicting a rate of the trans‐
planted kidney deterioration (Szeto et al., 2010), KIM-1 was proposed as an independent
predictor of the long term renal graft survival (Ting et al., 2012).
5. Proteins degrading extracellular matrix (ECM)
Urokinase-type plasminogen activator (uPA) and its specific receptor (uPAR) regulate renal
allograft function. Allogenic renal graft uPAR deficiency, strongly attenuates ischemia
reperfusion injury and acute kidney allograft rejection. Deficiency of uPAR in renal graft
diminished generation of reactive oxygen species and renal cells apoptosis (Gueler et al.,
2008). Therefore serum and urinary uPA may be treated as an early marker of the acute kidney
transplant rejection (Alachkar, 2012).
Matrix metalloproteinases (MMPs) are extracellular proteases which depend on bound Ca2+
and Zn2+ for activity. Urinary panel of metalloproteinases was proposed for the early diagnosis
of renal allograft rejection (Metzger et al., 2011; Sánchez-Escuredo et al., 2010; Hu et al., 2010).
Tissue inhibitors of metalloproteinases (TIMP) are extracellular inhibitors protease-specific,
which bind tightly to the activated protease, blocking its activity. Presently 2% to 4% of renal
allografts are rejected one year after from transplantation, because of chronic allograft injury.
Mazanowska et al. (Mazanowska et al., 2011) suggest that determination of TIMP in urine may
confirm the process of an active rejection of the transplanted kidney.
6. Immunological mediators of inflammatory state and fibrosis of renal
tissue
Urinary chemokines CXCL9 and CXCL10 may be treated as noninvasive screening markers
of renal graft rejection in patients with interstitial fibrosis and tubular atrophy (IF/TA), leading
to shorter life span of renal graft (Jackson et al., 2011; Schaub et al., 2009). Urinary CXCL10
may be a useful noninvasive screening test for tubulitis in renal graft recipients, and urinary
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CXCL10 concentration above 1,97 ng /mmol of creatinine is a threshold for consideration of
renal biopsy (Ho et al., 2011).
6.1. Immunological markers of renal inflammatory state
Macrophage inflammatory protein 3alpha (MIP-3alpha), chemokine C-C ligand 20
(CCL20) is a major chemokine expressed by epithelial cells that attracts immature dendritic
cells (DC). Graft-infiltrating dendritic cells (DC) and alloreactive T lymphocytes play a critical
role in renal allograft rejection. Renal proximal tubular epithelial cells (TEC) are considered as
an active players in the attraction of leukocytes during renal inflammatory responses. A
significant increase in the excretion of major intrinsic protein MIP-3α/CCL20 to urine was
observed in renal graft recipients with symptoms of graft rejection (Woltman et al., 2005; Peng
et al., 2008).
Growth-related oncogene-alpha (Gro-alpha) is an analog of the keratinocyte-derived
chemokine(KC). An increase in serum and urinary analog of Gro-alpha in the experimental
renal damage appears the earliest and persists the longest among the 18 chosen cytokines and
chemokines (Molls et al., 2006). Serum and urinary Gro-alpha were the highest 3 hours after
ischemia, while histological changes were evident after one hour, whereas serum creatinine
increased 24 hours after ischemia. Urinary concentration of Gro-α increased significantly in
renal graft recipients who required dialysis in comparison to people with normal renal graft
function. Urinary Gro-α is considered as an early marker of diagnosis and prognosis of acute
kidney injury (AKI) resulted from ischemia (Molls et al., 2006). It was reported that Gro-alfa,
significantly increased in patients who received cadaver kidney with poor function and from
living donors with minimal ischemia. Therefore determination of KC and Gro-α may be used
as biomarkers in the diagnosis of ischemic acute renal failure (ARF) and in the early diagnosis
and prognosis of renal ischemia-reperfusion injury (IRI). IRI is the most frequent cause of acute
kidney injury (AKI) and acute renal failure in delayed function graft received from a cadaver
(Molls et al., 2006).
Interleukin (IL-18) is a proinflammatory cytokine released to urine by epithelium of renal
proximal tubules after stimuli of nephrotoxic factor. Urinary IL-18 concentration >100 pg/mg
of urinary creatinine is a good diagnostic marker of the acute renal damage and mortality of
patients in intensive care units (Parikh et al., 2005) as well as a predictor of the delayed graft
function. It seems that urinary IL-18 helps for a detection of the very early stage of kidney
damage caused by ischemia or tubular nephrotoxins and plays a role in detecting prerenal
nitrogenemia, chronic renal insufficiency and urinary tract infection (Parikh et al., 2005).
Furthermore urinary Il-18 is an early predictive biomarker of the acute kidney injury after
cardiac surgery (Parikh et al., 2005). IL-18- proinflammatory cytokine caspase-1 dependent
(both derived from ischemic renal proximal tubular cells) is a proinflammatory cytokine
activated in damaged renal tubules by caspase -1 and released to urine in a case of the acute
kidney injury (AKI). A significant increase in urinary concentration of IL –18 and NGAL after
transplantation, however before delay in the renal graft function, was found. IL-18 is also a
predictor of the AKI severity preceding the increase in serum creatinine (Dinarello, 1999).
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Granzymes (granule-associated enzymes) are serine proteases (27-32kDa) of the chymotrypsin
family. Granzyme B (GzmB) and Fas-ligand (FAS-L) are cytotoxic molecules involved in the
acute renal graft rejection (AR) by the induction of DNA fragmentation of damaged cells
(Yannaraki et al., 2006). Granzyme A (GzmA) is a specific noninvasive immunological
biomarker for monitoring renal graft condition which facilitate diagnosis and treatment after
transplant complications. Granzyme A (GzmA) besides involvement in apoptosis may act as
mitogen of B lymphocytes. GzmA is a noninvasive biomarker differentiating patients with
subclinical and acute renal graft rejection from patients with renal tubular necrosis or persons
with stabile renal graft (van Ham et al., 2010 ).
6.2. Immunological markers of renal fibrosis
Chemokine regulated upon activation in normal T cells expressed and secreted (RANTES/
CCL5) is a chemokine of the beta subfamily secreted by macrophages and T lymphocytes.
RANTES can signal through CCR1, CCR3, CCR5 and US28(cytomegalovirus receptor)
receptors. It is chemoattractant towards monocytes, memory T cells(CD4+/CD45RO+),
basophils, and neutrophils. RANTES occurs in increased amounts in diseased kidneys and
indicate on interstitial inflammatory changes of the tubular cells at the early stages of acute
kidney injury, skin or heart graft rejection (Koga et al., 2000; Gwinner, 2007). RANTES
expressed in renal different cells (mesanglial cells, endothelium of renal tubules, fibroblasts,
lymphocytes) plays an active role in acute and chronic kidney inflammation and development
of tubule-interstitial damage. (Baer et al., 2005) reported absence of significant differences in
plasma and urinary RANTES in patients with acute renal graft rejection and recipients with
normal graft function. Therefore RANTES is not suitable for detection of early kidney graft
rejection. However an significant increase in the serum and urinary RANTES was observed
immediately after renal transplantation which may reflect an activation of the immunological
systems.
Transforming growth factor beta (TGF-β) is responsible for exacerbation of fibrosis, controls
growth and differentiation of cells and production of extracellular matrix as well as regulates
cellular migration. A participation of TGF-ß1 in lung and kidney fibrosis during chronic
allograft rejection was reported by (Awad et al.,1998; Bartnard et al., 1990). Increased excretion
of urinary TGF-β was proposed as a marker of the intrarenal production and activity of TGF-
ß1 in kidney. An increase in the urinary TGF-ß1 was reported in different nephropathies
particularly significant in patients with heavy proteinuria (Schnaper et al., 2003; Böttinger &
Bitzer, 2002). The 6-12 month immunosuppression with cyclosporine in renal-transplant
recipients caused development of a chronic interstitial nephropathy with decreased GFR.
Cyclosporine A (CsA) facilitate the expression of TGF-β in renal tubular cells and cells of renal
juxtaglomerular apparatus. Furthermore, CsA stimulates T lymphocytes and endothelial cell
to a TGF-β 1 production. Expression of TGF-β 1 is CsA dose dependent. High doses of CsA
are risk factors of chronic graft dysfunction, among kidney recipients (Boratyńska et al., 2003).
Vascular endothelial growth factor (VEGF) a dimeric protein containing subunits constituted
of 121, 165, 189 or 206 amino acids is a proangiogenic growth factor. In patients with symptoms
of acute renal graft rejection high urinary VEGF concentration was found in comparison to
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people with normal function of renal graft. Therefore monitoring of urinary VEGF was
proposed as a marker of detection acute renal graft rejection and the evaluation of the
effectiveness of immunotherapy (Peng et al., 2008; Alachkar, 2012).
Hepatocyte growth factor (HGF) induces angiogenesis by stimulation proliferation, migration
and adhesion of endothelial cells. Urinary HGF concentration was highest at the first day after
transplantation, decreased quickly within next week and later remained on the same level.
Determination of the urinary HGF immediately after kidney transplantation may be a quick,
noninvasive marker of long lasting renal graft function (Kwiatkowska et al., 2010).
Endothelin-1 (ET-1) is the strongest vasoconstrictory factor produced by endothelium of blood
vessels, glomerular mesangium, renal tubular cells, fibroblasts and macrophages. ET-1
regulates fibrosis by joining interstitial fibroblasts, initiation its proliferation and synthesis of
extracellular matrix as well as chemotactic action on macrophages. ET-1 is degraded mostly
in lungs and kidneys. Urinary ET-1 excretion reflects its renal production. Increase in ET-1
gene expression and urinary excretion correlates positively with proteinuria and negatively
with creatinine clearance (Grenda et al., 2007; Saurina et al., 2007). Plasma and urinary ET-1
concentrations are increased in patients treated with Cyclosporine A and FKJ506. Cyclosporine
A and FK506 are calcineurine inhibitors broadly applied for immunosuppression in kidney
transplant patients. Cyclosporine A and FK506 significantly improve graft survival. However
graft recipients may die because of cardiovascular complications as 80% of renal graft recipi‐
ents reveal vascular hypertension. Increased ET-1 concentration may reflect activation of the
ET-1 system in chronic insufficiency of transplanted kidney (Slowinski et al., 2002).
Monocyte chemotactic peptide-1 (MCP-1/CCL2) mediates recruitment of inflammatory cells:
monocytes/macrophages and lymphocytes T, to renal tubules damaged by high concentrations
of albumin in tubules. A strict relationship between albuminuria, urinary MCP-1/CCL2 and
macrophage infiltration in damaged loci, was demonstrated (Urbschat et al., 2011; Viedt &
Orth, 2002). In patients with acute renal graft rejection urinary concentration of MPC-1,
determined by ELISA, was ten times higher than in patients with stable graft function
(Dubiński et al., 2008). Since chronic damage to renal graft as a result of gradual fibrosis and
tubular damage (IF/TA) is the most frequent cause of graft loss, urinary CCL2 may be treated
as an independent prognostic marker of development of IF/TA during the next 24 months (Ho
et al., 2010).
Fractalkine (CX3CL1) is a chemokine from the CX3C group of complement system, stimulated
by CX3CR1 receptor connected to G protein. In experimental renal disease induced by albumin
overload and proceeding with proteinuria, increased expression of fractalkine gene correlates
with applied albumin dose and time of albumin interaction with the renal tubular cells
(Donadelli et al., 2003). Fractalkine urinary concentration is a noninvasive method for detection
of acute renal graft rejection (Peng et al., 2008).
Angiotensin II (Ang II) is an important intrarenal factor favoring processes of inflammation
and fibrosis by an increase in the expression of the proinflammatory genes (IL-6, TNFα, MCP-1,
RANTES). According to latest opinions the urinary concentration of angiotensinogen, reflects
amounts of produced Ang II inside the kidney better, than immediate evaluation of Ang II in
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the urine. Improvement of the ELISA method for determination of human urinary angioten‐
sinogen, may allow to disclose influence of Ang II on intrarenal destructive processes
(Yamamoto et al., 2007; Katsurada et al., 2007).
Complement is a major mediator system in pathogenesis of various kidney diseases. The
presence and localization of complement components in glomerulus and/or the tubule-
interstitial area provides diagnostic tools for several human renal diseases (Zoja et al., 2003;
Lisowska-Myjak, 2010). Increase in urinary excretion of complement components in patients
with proteinuria significantly correlate with urinary excretion of total proteins and decrease
in renal function. Therefore increase in urinary C5b-9 in patients with proteinuria may by
prognostic marker for the development of kidney insufficiency (Eddy, 2002). Accelerated C3
activation at renal proximal tubules in diseases proceeding with proteinuria are result of
increased intratubular protein catabolism, with accompanying increase in ammonia (activator
of alternative pathway of complement activation) (Morita et al., 2000; Abbate et al., 2008;
Sheerin et al., 2008; Lederer et al., 2003). Everyday urinary determination of C5A and TCC may
be a sensitive and reliable marker of the acute insufficiency of the transplanted kidney and
predictor of graft rejection (Müller et al., 1997).
Galectin 3 (Gal-3) is a beta-galactoside-binding lectin in diverse fibrotic tissues. Gal 3 plays
an important role in fibrosis of transplanted kidney and may be a potential marker of chronic
allograft impairment (CAI) (Dang et al., 2012).
7. Tubular enzymes
Currently, in clinical diagnostic practice for renal parenchymal tubular impairment, assess‐
ment of urinary enzymes is used. Particular advantage of urinary enzymes determination is
its localization in appropriate renal cells (glomeruli, tubules) and their organelles (cytoplasm,
lysosomes, membranes), which may deliver detailed information concerning nature and
dimension of the renal cells damage and an evaluation of their dysfunction or necrosis
(Westhuyzen et al., 2003; Trof et al., 2006). Routine, simple, cheap and broadly available
spectrophotometric methods are applied for measurement of urinary enzymes activity. An
increase in urinary excretion of enzymes reflects damage of particular renal section (D‘Amico
& Bazzi, 2003; Jung et al., 1986). Determination of urinary FBP-1,6, NAG, glutathione-S-
transferase and pyruvate kinase has recently been recommended for the diagnosis of kidney
disease and early detection of transplant rejection (Kotanko et al., 1997; Kotanko et al., 1986).
7.1. Enzymes of brush border membranes
Gamma-glutamyltransferase (GGT) – is connected with cellular membranes of liver, kidney,
pancreas and prostatic gland (Kuźniar et al., 2006). Serial determination of urinary enzymes
is a reliable proof for nephrotoxicity resulted from long term cyclosporine A treatment. Lack
of enzymuria indicates a recovery of renal tubules to normal function (Tataranni et al., 1992).
Alkaline phosphatase (AP) – is present in cellular membranes of many tissues, mainly bonds,
liver and intestine where it participates in metabolism of organic phosphates. Frequent cause
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of deterioration to the renal graft function is nephrotoxicity of immunosuppressive drugs (e.g.
cyclosporin A) reflected by increase in activity of urinary enzymes : ALP, LDH, GGT, beta-
glucuronidase (Refaie et al., 2000; Takahashi et al., 1989; Simić-Ogrizović et al., 1994).
Alanylaminopeptidase (AAP) – proteolytic enzyme degrading oligopeptides. Increases in
urinary concentration of hexosaminidase and AAP accompany acute renal tubular necrosis,
renal graft rejection or nephrotoxic action of immunosuppresive drugs (e.g. cyclosporin A)
administered to patients after kidney transplantat (Kuźniar et al., 2006; Lisowska-Myjak,
2010; Santos et al., 2010). Increases in urinary excretion of tubular enzymes testifies tubular
brush border membrane damage with a loss of microvillus structure (Westhuyzen et al., 2003).
7.2. Cytosolic enzymes
Glutathione S-transferase (alpha-GST, pi-GST) is a specific cytoplasmic enzyme of tubular
epithelial cells consisting of two isoenzymes: α-GST with alkaline and πi-GST with acidic pH
optimum. GST-α appears in epithelium of proximal tubular cells and GST-π in distal tubules
(Branten et al., 2000). Determination in urine α-GST and, π-GST is applied to diagnosis acute
renal graft rejection with acute tubular necrosis (Kuźniar et al., 2006; Polak, 1999). Differenti‐
ated increase in urinary GST- alpha and GST- pi excretion may point to localization of an
nephron damage (Westhuyzen et al., 2003; Trof et al., 2006; Herget-Rosenthal et al., 2004;
Branten et al., 2000; Gautier et al., 2010).
Fructose-1,6-bisphosphatase (FBP-1,6) is localized mostly in contorted and to less extend in
straight part of proximal renal tubules, similarly to hexosaminidase and GST, points to accurate
localization of damaged nephron (Trof et al., 2006; Kotanko et al., 1986). Increase in urinary
FBP-1,6 was observed in patients after kidney transplantat. Urinary FBP-1,6 excretion was
significantly lower in patients with median of cold ischemia below 22 hours, than above 22
hours. Even in lack of graft dysfunction, in situation where it is a long time of cold ischemia,
urinary excretion of FBP-ase correlates with a degree of damage to the renal tubules (Kotanko
et al., 1997). It was reported that a panel of urinary enzymes activities: FBP-ase, glutathione S-
transferase, N-acetyl-beta-D-glucosaminidase and pyruvate kinase is a good marker of the
cyclosporin A nephrotoxicity (Kotanko et al., 1986).
7.3. Renal lysosomal enzymes
N-acetyl-β-D-hexosaminidase (HEX) is one of the most frequently determined urinary
markers of renal tubules damage, because its activity increased at early steps of the renal
tubules damage, before occurrence of disturbances in renal excretory function. Hexosamini‐
dase localized mainly in renal proximal tubular cells, is a specific marker for proximal tubular
cells because its high molecular weight (> 130 kDa) excludes its glomerular filtration. In the
course of active kidney disease HEX activity is constantly increased. An increase in urinary
activity HEX and its isoenzyme B indicate on damage in the renal tubular cells. Therefore
urinary HEX and particularly HEX B activity may be treated as a specific marker of damage
in the renal proximal tubules of the transplanted kidney (Liangos et al., 2007; Holdt−Lehmann
et al., 2000;).
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8. Markers of renal ischemia/reperfusion injury
Leukocyte elastase (LE, neutrophil elastase), is a 30-kDa glycoprotein serine protease released
from neutrophils as a mediator of ischemia/reperfusion injury after renal transplantation.
Urinary LE is a simple noninvasive marker of the neutrophil activation after renal transplantat
(Zynek-Litwin et al., 2010).
9. Biomarkers of dystal renal tubules
In the assessment of distal renal tubule dysfunction it is advised to examine urine osmo‐
larity  and/or  determination  Tamm-Horsfall  glycoprotein  as  well  as  urinary  kallikrein
(Bhoola et al., 1992).
Renal kallikrein is a serine protease which releases vasodilatatory peptides: bradykinine and
calidine, from kininogen. Renal kallikrein is present in renal collecting tubules and is released
to tubular fluid by terminal section of dystal segment of nephron (Manucha & Vallés, 1999;
Thongboonkerd & Malasit, 2005). An increase in activity of urinary kallikrein was observed
in insufficiency and loss of the renal graft function (Krimkevich, 1990).
AnnexinA11 (ANXA11). Annexins are calcium-binding proteins which binds to acidic
phospholipid and F-actin. Depending on calcium concentration Annexin A 11 participate in
signal transduction, cell proliferation, regulation of vesicular transport and interaction with
the cell membranes. Annexin occurs in high quantities in renal distal tubular cells and
epithelium of renal glomeruli. Annexin physiologic role seems to be related to cell apoptosis
(Rodrigues-Garcia et al., 1996). Significant correlation between urinary Annexin V and other
proteins and lack of correlation with urinary urea and creatinine concentration suggests that
Annexin V is not an indicator of kidney function, but rather reflects local kidney damage
(Matsuda et al., 2000). Annexin A11 may act as an atypical calcium channel and useful marker
of acute and chronic renal graft rejection (Srivastava et al., 2011)
Renal papillary antigen-1 (RPA-1) a renal papillary antigen-1, sensitive and specific antigen
of renal papillary cells is a sensitive and specific urinary marker of damage renal collecting
tubules (Gautier et al., 2010).
Prominin-2 (PROM-2) analog of CD133 (prominin-1) is an membrane glycoprotein (112kD)
with the highest expression in epithelial cells of matured kidney. Prominin-2 is a cholesterol-
binding protein associated with apical and basolateral plasmalemmal protrusions in polarized
epithelial cells and released into urine (Florek et al., 2007) and a novel marker of distal tubules
and collecting ducts of the human and murine kidney (Jászai et al., 2010).
μ-glutathione-S-transferase (μ-GST) is a conjugating glutathione with electrophilic com‐
pounds that occurs in epithelial cells of ascending part of Henle’s loop (Gautier et al., 2010;
Holmquist & Torffvit, 2008). After nephrotoxic drugs treatment (e.g. cisplatin) μ-GST quickly
appear in urine. μ-GST is a more specific marker of nephrotoxicity (AUC 1.000) than α-GST
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(AUC 0.984) or albuminuria (AUC 0.984). μ-GST is an early biomarker for Henle’s loop and
distal tubules damage (Tonomura et al., 2010).
10. The future of biomarkers
Development of new technologies involved in molecular biology, analysis of m-RNA expres‐
sion, proteomics and metabolomics create a possibility of discovery of new markers for early
diagnosis of AKI and IF/TA. Relatively new method of microarrays (microarrays of cDNA and
oligonuclotides- DNA chips) are sets of molecular probes attached to solid background in
strictly determined order constituting two dimensional system of microscopic areas with
defined sequences of nucleic acid. Microarray technology allow for detection of thousands of
molecules of nucleic acids due to possibility of performing simultaneously many hybridization
experiments (Dean et al., 2012). DNA microarrays technology permit for simultaneous
monitoring expression of many genes (Scian et al., 2011). Identification of these genes constitute
further step in earlier diagnosis and better prognosis of TA/IF(tubular atrophy/interstitial
fibrosis).
Proteomic techniques Recently broadly applied proteomic techniques facilitate discovery of
new biomarkers useful in evaluation of transplanted kidney function. Proteomics apply
protein analysis using techniques such as MS e.g. (MALDI-TOF-Matrix Assisted Laser
Desorption Ionisation - Time of Flight; SELDI-TOF-Surface Enhanced Laser Desorption
Ionisation - Time of Flight; ES multielementary I - LTQ – FTICR-Electrospray Ionisation - Linear
Trap Quadrupole - Fourier Transform Ion Cyclotron Resonance). Proteomics combine series
of techniques for simultaneous analysis of hundreds or thousands of cells proteins. Proteomics
objective is not only creation of the list of important proteins, but first of all exploration of
differences in protein profiles of healthy and diseased people. Proteomic identification of
urinary protein profiles is an noninvasive method for detection of renal proximal tubules
dysfunction of transplanted kidney (Srivastava et al., 2011; Gwinner, 2007). Proteomic
techniques are alternative for diagnostics based on single markers, because it allows for
simultaneous analysis of large numbers of protein and peptide markers creating specific
„finger print” of disease. Proteomics determines pattern of expression or secretion taking into
account qualitative and quantitative relations between peptides and proteins produced in
defined pathophysiological conditions.
Metabolomics based on analysis sets of metabolites connected with proteins, lipids, carbohy‐
drates, hormones, etc. evaluate qualitative and quantitative relations between particular
metabolites. Due to metabolomics it is possible to determine definite metabolites characteristic
for specific groups of diseases and changes occurring under influence of genetic and patho‐
physiological stimuli (Wishart, 2006).
New technologies and bioinformatics tools offer tremendous research possibilities which
should make possible now and in the future precise monitoring of kidney graft, allow early
detection and treatment of renal graft rejection and allow both for preventing and treatment
of renal transplant complications as well as to improve number of long term patients survival.














β2M,α1M + + Johnston et al., 2011; Du et al., 2011;
Câmara et al., 2009;Kuźniar et al., 2006
Netrin-1 + Ramesh et al., 2010; Urbschat et al., 2011
NGAL + Ramesh et al., 2010; Nauta et al., 2011;
Przybyłowski et al., 2011; Halawa, 2011;
Devarajan, 2011; Hall&Parikh, 2010; Du et
al., 2011;Ting et al., 2012
IL-16,IL-2,IL-6,IL-18,TNF + + Alachkar er al., 2010; Halawa, 2011;
Devarajan, 2011; Reinhold et al., 2012;
Urbschat et al., 2011
KIM-1 + + Nauta et al., 2011; Halawa, 2011;
Devarajan,2011; Hall &Parikh, 2010; Du et
al., 2011; Ting et al., 2012; Urbschat et al.,
2011
NAG + Nauta et al. 2011; Câmara et al., 2009; Ting
et al., 2012; Kuźniar et al., 2006; Alachkar et
al., 2010
H-FABP, L-FABP + + Nauta et al., 2011; Przybylowskiet al., 2011
Cystatin C + Przybylowski et al., 2011; Hall &Parikh, 2010
CXCL9,CXCL10 + + Ho et al., 2011; Schaub et al., 2009; Jackson
et al., 2011; Ting et al., 2012
alpha-GST, pi-GST + + Câmara et al., 2009;Hall &Parikh, 2010; Ting
et al., 2012; Kuźniar et al., 2006;
Oberbauer , 2008
GzmA,GzmB (granzyme) + van Ham et al., 2010; Peng et al., 2008;
Oberbauer, 2008
Galectin-3(Gal-3) + Dang et al., 2012
Integrin α3, integrinβ2 + + Srivastava et al., 2011
ANXA11 + + Srivastavaet al., 2011
sVCAM + Reinhold et al., 2012
MMP7, MMP-8 + Metzger et al., 2011; Ling et al., 2010
LDH, ALP, γ-GT, AAP + Refaie et al., 2000;Kuźniar et al., 2006
















OX40,OX40L,PD-1 + Afaneh et al., 2010
HLA-DR + Ting et al., 2010
CTGF + Yue et al., 2010; Bao et al., 2008
uPA + Alachkar , 2012
Leukocyte elastase (LE) + + Zynek-Litwin et al., 2010
SERPING1 + Ling et al., 2010
TIMP1 + Ling et al., 2010
MIP-1delta, + + Hu et al., 2009
Osteoprotegerin + + Hu et al., 2009
VEGF + Peng et al., 2008
fractalkine + Peng et al., 2008
MCP-1 + Dubiński et al., 2008; Urbschat et al., 2011
RBP + Kuźniar et al., 2006; Câmara et al., 2009
Perforin + Oberbauer, 2008
FOXP3 + Oberbauer, 2008
Table 1. Urinary biomarkers for the early detection of acute and chronic allograft dysfunction.
11. Conclusion
In this chapter we presented traditional and new biomarkers for diagnostics and monitoring
condition of transplant kidneys. Urine is practical, easy to obtain, noninvasive material for
diagnosis of kidney diseases. Numerous reports from molecular biology, genetics, proteomics
and metabolomics disclosed an array of new markers specifically connected with damage of
specific nephron segments in the course of successive steps of disease. Particular expectations
are connected with proteins represented particular nephron section, or produced locally in the
place of nephron damage. Presence of cytokines and chemokines in urine is an early sign of
renal inflammatory state, due to influx of granulocytes to the damaged nephron area. Majority
of traditional biomarkers, particularly enzymuria retains diagnostic value in an evaluation of
the renal tubules function. Multitude of presented biomarkers suggest their limited diagnostic
value. Discovering universal marker seems to be very difficult. However, it is potentially more
fruitful to identity the putative biomarker proteins useful in diagnostics of kidney disease.
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Scientiscs are still looking for the “kidney troponin”. Actually, more than ten promising
biomarkers for kidney damage have been identified. The most relevant and the best studied
substances are neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, kidney injury
molecule-1 (KIM-1), beta-2 microglobulin (β2M), and interleukin-18 (IL- 18). In kidney
allograft recipients, urinary KIM-1 expression provides prognostic information in relation to
the rate of renal function decline, irrespective of the kidney pathology (Ting et al., 2012; Han
et al., 2002; Szeto et al., 2010).
Validation of those kidney markers in various pathologic conditions is actually ongoing.
However, the majority of publications reviewed are small cross-sectional studies, and there
are only a handful of longitudinal studies. Another important point is that biomarkers only
have clinical value if the results are reproducible. However none of the biomarkers reviewed
here have been studied in more than 2 longitudinal trials so their clinical applicability needs
to be confirmed in good quality, long-term, large longitudinal trials.
Among enzymes which retain high diagnostic value in diagnostics of renal diseases are:
hexosaminidase and its isoenzyme B as a marker of the proximal tubular damage as well as
AAP or GST as a marker of the tubular brush border membrane. Cytosolic FBP-1,6 is of great
diagnostic value for assessment of graft function. It is commonly believed that appropriate
panel of urinary proteins and enzymes may by a practical marker for evaluation of the nephron
function of transplant kidney and prognosis of the renal allograft fate. In the future, discovery
of new biomarkers and research techniques may change practical approach to treating patients
with renal grafts. In summary we feel it is necessary for an international body to develop a
renal marker utility grading system, to evaluate the usefulness of particular markers of
nephron function and to make recommendations for the use of renal transplant markers,
similar to those instilled for tumor markers (Hayes et al., 1996; Locker et al., 2006).
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